According to court documents from Gioia's 2021 product liability lawsuit, she alleged that taking Invega Sustenna caused her to suffer a wide range of severe neurological and physical injuries, and that she was not adequately warned of these risks (lack of informed consent). She also claimed that these side effects led her to fail her medical board examinations, ultimately ending her career as a primary care physician. Below is a summary of the specific conditions she listed:

Neurological and Nervous System Injuries

• Peripheral Neuropathy (nerve damage)
• Horner's Syndrome (a rare nerve pathway disorder affecting the face and eye)
• Facial Nerve Damage
• Motor Tremors and Vocal Tics
• Memory Issues and Confusion
• Loss of Taste Sensation

Systemic and Metabolic Conditions

• Metabolic Syndrome (a cluster of conditions increasing the risk of heart disease, stroke, and diabetes)
• Hypertension (high blood pressure)
• Diabetes
• Stroke
• Subclinical Hypothyroidism (an underactive thyroid)

Psychological Condition

• Post-Traumatic Stress Disorder (PTSD)

Note: The number of Invega Sustenna injections she received and her age at the time were not found in available court documents.

Despite her detailed claims, Gioia's lawsuits were ultimately unsuccessful. A New York federal judge dismissed her case against Janssen, noting that the alleged side effects she listed were already included on Invega's FDA-approved warning label, which includes, among other risks, hyperglycemia, diabetes, hypertension, stroke, and tardive dyskinesia. As the court stated: "he fact that suffered from certain conditions that were also identified risks of ingesting is tragic, but cannot alone make plausible a claim that misrepresented or hid those risks in some way." Subsequent lawsuits were similarly dismissed for lack of subject matter jurisdiction (the court concluded it had no authority to hear her claims) or failure to state a legal claim, with the court noting that Gioia had "failed to prosecute" her cases.

It is also important to understand the "learned intermediary" doctrine, under which a drug manufacturer's duty to warn runs to the prescribing physician, not directly to the patient. This means a patient like Gioia must prove that the warnings given to her doctor were inadequate—a difficult legal barrier that she did not overcome.

However, the court's conclusion that nearly all of Gioia's alleged side effects were already on the warning label deserves closer scrutiny. While the FDA-approved label for Invega Sustenna does list diabetes, hypertension, and stroke, it does not list permanent memory loss, persistent cognitive impairment, or irreversible nerve damage. The label's "Potential for Cognitive and Motor Impairment" section warns only of transient effects during treatment—advising caution when operating machinery—and states that patients should avoid such activities "until they are reasonably certain" the drug does not affect them adversely. Nowhere does the label warn that cognitive deficits may persist after stopping the medication. The label also does not mention Horner's syndrome, peripheral neuropathy (damage to nerves outside the brain and spinal cord), or vocal tics as potential side effects.

In short, the Invega label doesn't warn about permanent brain damage.

If Gioia's memory issues were indeed permanent, then the manufacturer Janssen's warnings were objectively incomplete. Should a drug's label warn only of temporary side effects, even when permanent damage is possible?

---

https://www.vitallaw.com/resolve/document/lld015738c0007e091000ba0b000d3a8abb4e05?u=0ceeb905-1f47-4ae3-9cc1-08690d575e4c&cfu=Legal&cpid=WKUS-Legal-Cheetah&uAppCtx=lrus-ps&src=ml

CourtListener.com (a non-profit project that archives legal opinions and makes them freely available):

• https://www.courtlistener.com/opinion/9839047/gioia-v-janssen-pharmaceuticals/?preview=true&site_id=312
• https://www.courtlistener.com/opinion/9845094/gioia-v-patterson-belknap-webb-tyler/?stat_Errata=on&stat_In-chambers=on&stat_Non-Precedential=on&stat_Precedential=on&stat_Relating-to+orders=on&stat_Separate+Opinion=on&stat_Unknown+Status=on&type=o